P834: MULTIPARAMETRIC FLOW CYTOMETRY FOR THE DETECTION OF CIRCULATING TUMOR CELLS IN PATIENTS WITH IGM MONOCLONAL GAMMOPATHIES

P834: MULTIPARAMETRIC FLOW CYTOMETRY FOR THE DETECTION OF CIRCULATING TUMOR CELLS IN PATIENTS WITH IGM MONOCLONAL GAMMOPATHIES

Bibliographic Details
Main Authors:	Ioannis Kostopoulos, Stamatia Skourti, Nefeli Mavrianou Koutsoukou, Christine Liacos, Alexandra Papadimou, Kostantina Taouxi, Foteini Theodorakakou, Despina Fotiou, Evangelos Terpos, Ourania Tsitsiloni, Meletios A. Dimopoulos, Efstathios Kastritis, Tina Bagratuni
Format:	Article
Language:	English
Published:	Wiley 2023-08-01
Series:	HemaSphere
Online Access:	http://journals.lww.com/10.1097/01.HS9.0000970240.47046.3b

Similar Items

<i>MYD88</i> Wild Type in IgM Monoclonal Gammopathies: From Molecular Mechanisms to Clinical Challenges
by: Tina Bagratuni, et al.
Published: (2023-09-01)

Single‐cell analysis of MYD88L265P and MYD88WT Waldenström macroglobulinemia patients
by: Tina Bagratuni, et al.
Published: (2024-02-01)

P826: THE CIRCULAR RNA OF THE CHAPERONIN-CONTAINING TCP1 SUBUNIT 3 GENE (CIRC-CCT3) IS OVEREXPRESSED IN MULTIPLE MYELOMA AND PREDICTS A FAVORABLE PROGNOSTIC OUTCOME, INDEPENDENTLY OF THE R-ISS STAGING
by: Maria Papatsirou, et al.
Published: (2023-08-01)

Prevalence of MGCS Among Patients With Monoclonal Gammopathies
by: Foteini Theodorakakou, et al.
Published: (2023-06-01)

ciRS‐7 circular RNA overexpression in plasma cells is a promising molecular biomarker of unfavorable prognosis in multiple myeloma
by: Maria Papatsirou, et al.
Published: (2024-08-01)

Future Developments in the Treatment of AL Amyloidosis
by: Foteini Theodorakakou, et al.
Published: (2022-02-01)

Daratumumab plus CyBorD for patients with newly diagnosed light chain (AL) amyloidosis
by: Foteini Theodorakakou, et al.
Published: (2021-11-01)

P861: PERSISTENT BONE MARROW AND IMAGING MRD NEGATIVITY AS CRITERIA TO STOP LENALIDOMIDE MAINTENANCE FOLLOWING ASCT: PRELIMINARY RESULTS OF A SINGLE-CENTER PROSPECTIVE COHORT STUDY
by: Panagiotis Malandrakis, et al.
Published: (2023-08-01)

Monoclonal antibody-based therapies for Waldenström's macroglobulinemia
by: Despina Fotiou, et al.
Published: (2022-01-01)

PB2124: EFFICACY AND IMMUNE MODULATION OF DARATUMUMAB PLUS IMID COMBINATION IN PATIENTS REFRACTORY TO BOTH AGENTS“
by: Ioannis Kostopoulos, et al.
Published: (2023-08-01)

Antibody Response After Initial Vaccination for SARS-CoV-2 in Patients With Amyloidosis
by: Efstathios Kastritis, et al.
Published: (2021-08-01)

Systemic AL Amyloidosis: Current Approaches to Diagnosis and Management
by: Despina Fotiou, et al.
Published: (2020-08-01)

Increased serum B‐cell maturation antigen levels evaluated with an Elecsys‐based serum B‐cell maturation antigen assay have a negative prognostic value in patients with newly diagnosed multiple myeloma
by: Evangelos Terpos, et al.
Published: (2025-02-01)

Belantamab mafodotin, lenalidomide and dexamethasone in transplant-ineligible patients with newly diagnosed multiple myeloma: Part 1 results of a phase I/II study
by: Evangelos Terpos, et al.
Published: (2024-02-01)

tRNA Derivatives in Multiple Myeloma: Investigation of the Potential Value of a tRNA-Derived Molecular Signature
by: Paraskevi Karousi, et al.
Published: (2021-12-01)

Increased angiogenesis and enhanced bone formation in patients with IgM monoclonal gammopathy and urticarial skin rash: new insight into the biology of Schnitzler syndrome
by: Evangelos Terpos, et al.
Published: (2012-11-01)

PB2127: REAL-WORLD EFFECTIVENESS AND SAFETY OF BELANTAMAB MAFODOTIN IN TRIPLE CLASS REFRACTORY PATIENTS WITH MULTIPLE MYELOMA
by: Ioannis Ntanasis-Stathopoulos, et al.
Published: (2023-08-01)

Use of Oral Antivirals Ritonavir-Nirmatrelvir and Molnupiravir in Patients with Multiple Myeloma Is Associated with Low Rates of Severe COVID-19: A Single-Center, Prospective Study
by: Vassiliki Spiliopoulou, et al.
Published: (2023-03-01)

Efficacy and immune modulation associated with the addition of IMiDs to Daratumumab backbone in multiple myeloma patients refractory to both drug classes: resetting synergistic activity
by: Ioannis V. Kostopoulos, et al.
Published: (2024-02-01)

Upfront Daratumumab With Lenalidomide and Dexamethasone for POEMS Syndrome
by: Maria Gavriatopoulou, et al.
Published: (2020-06-01)

The Cytogenetic Profile of Primary and Secondary Plasma Cell Leukemia: Etiopathogenetic Perspectives, Prognostic Impact and Clinical Relevance to Newly Diagnosed Multiple Myeloma with Differential Circulating Clonal Plasma Cells
by: Stefanos I. Papadhimitriou, et al.
Published: (2022-01-01)

Disease control should be the goal of therapy for WM patients
by: Efstathios Kastritis, et al.
Published: (2017-11-01)

P884: BELANTAMAB MAFODOTIN PLUS LENALIDOMIDE AND DEXAMETHASONE IN TRANSPLANT INELIGIBLE PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA: UPDATED RESULTS FROM THE PHASE 1/2 BELARD STUDY
by: Evangelos Terpos, et al.
Published: (2023-08-01)

P928: OCULAR ADVERSE EVENTS AND FUNCTIONAL IMPACT IN TRANSPLANT INELIGIBLE, NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS TREATED WITH BELANTAMAB MAFODOTIN, LENALIDOMIDE AND DEXAMETHASONE IN A PHASE 1/2 TRIAL
by: Evangelos Terpos, et al.
Published: (2023-08-01)

Plasma Metabolomic Alterations Induced by COVID-19 Vaccination Reveal Putative Biomarkers Reflecting the Immune Response
by: Ioanna Dagla, et al.
Published: (2022-04-01)

Tixagevimab/Cilgavimab as Pre-Exposure Prophylaxis against COVID-19 for Multiple Myeloma Patients: A Prospective Study in the Omicron Era
by: Ioannis Ntanasis-Stathopoulos, et al.
Published: (2023-09-01)

Exploring the molecular biomarker utility of circCCT3 in multiple myeloma: A favorable prognostic indicator, particularly for R‐ISS II patients
by: Maria Papatsirou, et al.
Published: (2024-01-01)

Mutations in the alternative complement pathway in multiple myeloma patients with carfilzomib-induced thrombotic microangiopathy
by: Maria Moscvin, et al.
Published: (2023-02-01)

Management and Outcomes of Anti-CD38 Refractory Patients: The Impact of Retreatment and of Subsequent Therapies
by: Efstathios Kastritis, et al.
Published: (2023-11-01)

Pomalidomide- and dexamethasone-based regimens in the treatment of refractory/relapsed multiple myeloma
by: Despina Fotiou, et al.
Published: (2022-05-01)

S198: EFFICACY AND SAFETY OF BELANTAMAB MAFODOTIN MONOTHERAPY IN PATIENTS WITH RELAPSED OR REFRACTORY LIGHT CHAIN AMYLOIDOSIS: A PHASE 2 STUDY BY THE EUROPEAN MYELOMA NETWORK
by: Efstathios Kastritis, et al.
Published: (2023-08-01)

Kinetics of Anti-SARS-CoV-2 Antibody Responses 3 Months Post Complete Vaccination with BNT162b2; A Prospective Study in 283 Health Workers
by: Evangelos Terpos, et al.
Published: (2021-07-01)

Comparative kinetics of SARS-CoV-2 anti-spike protein RBD IgGs and neutralizing antibodies in convalescent and naïve recipients of the BNT162b2 mRNA vaccine versus COVID-19 patients
by: Ioannis P. Trougakos, et al.
Published: (2021-08-01)

B03: SKELETAL-RELATED EVENTS AND ABNORMAL MRI PATTERN AT DIAGNOSIS ARE ASSOCIATED WITH INFERIOR OVERALL SURVIVAL IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA
by: Evangelos Terpos, et al.
Published: (2022-04-01)

The neutralizing antibody response post COVID-19 vaccination in patients with myeloma is highly dependent on the type of anti-myeloma treatment
by: Evangelos Terpos, et al.
Published: (2021-08-01)

Insights to SARS-CoV-2 life cycle, pathophysiology, and rationalized treatments that target COVID-19 clinical complications
by: Ioannis P. Trougakos, et al.
Published: (2021-01-01)

Second Booster BNT162b2 Restores SARS-CoV-2 Humoral Response in Patients With Multiple Myeloma, Excluding Those Under Anti-BCMA Therapy
by: Ioannis Ntanasis-Stathopoulos, et al.
Published: (2022-08-01)

Conservative Treatment of Bisphosphonate-Related Osteonecrosis of the Jaw in Multiple Myeloma Patients
by: Pelagia I. Melea, et al.
Published: (2014-01-01)

The utility of splenic imaging parameters in cardiac magnetic resonance for the diagnosis of immunoglobulin light-chain amyloidosis
by: Niki Lama, et al.
Published: (2022-03-01)

Peripheral Blood Immune Profiling of Convalescent Plasma Donors Reveals Alterations in Specific Immune Subpopulations Even at 2 Months Post SARS-CoV-2 Infection
by: Nikolaos Orologas-Stavrou, et al.
Published: (2020-12-01)